Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AKBA 
Akebia Ther (AKBA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: AKBA (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.4
1 Year Target Price $7.4
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0.33% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 776.88M USD | Price to earnings Ratio - | 1Y Target Price 7.4 |
Price to earnings Ratio - | 1Y Target Price 7.4 | ||
Volume (30-day avg) 4 | Beta 0.68 | 52 Weeks Range 1.33 - 4.08 | Updated Date 10/19/2025 |
52 Weeks Range 1.33 - 4.08 | Updated Date 10/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.18 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -17.91% | Operating Margin (TTM) 22.71% |
Management Effectiveness
Return on Assets (TTM) 0.88% | Return on Equity (TTM) -553.45% |
Valuation
Trailing PE - | Forward PE 24.63 | Enterprise Value 634597052 | Price to Sales(TTM) 3.81 |
Enterprise Value 634597052 | Price to Sales(TTM) 3.81 | ||
Enterprise Value to Revenue 3.11 | Enterprise Value to EBITDA 57.65 | Shares Outstanding 265145038 | Shares Floating 259799714 |
Shares Outstanding 265145038 | Shares Floating 259799714 | ||
Percent Insiders 3.56 | Percent Institutions 43.64 |
Upturn AI SWOT
Akebia Ther
Company Overview
History and Background
Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapeutics for patients with kidney disease. It was founded in 2007. Major milestones include the development of vadadustat and its subsequent regulatory pathways.
Core Business Areas
- Renal Therapeutics: Focuses on the development and commercialization of therapies for kidney disease, primarily vadadustat for anemia due to chronic kidney disease (CKD).
Leadership and Structure
Akebia is led by a management team with expertise in nephrology and drug development. The organizational structure includes departments for research, clinical development, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- Vadadustat: An oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor being developed for the treatment of anemia due to CKD. Market share is currently developing, and competition includes injectable erythropoiesis-stimulating agents (ESAs) and other emerging oral HIF-PH inhibitors. Major competitors are Amgen (AMGN) with Epogen and Aranesp and FibroGen (FGEN).
Market Dynamics
Industry Overview
The renal therapeutics market is driven by the increasing prevalence of chronic kidney disease and the need for improved treatment options for anemia. The market is characterized by established injectable therapies and emerging oral therapies.
Positioning
Akebia is positioned as a company developing an oral alternative to injectable ESAs for anemia due to CKD. Its competitive advantage lies in the convenience of oral administration and potentially improved safety profile.
Total Addressable Market (TAM)
The global anemia in CKD market is estimated to be billions of dollars. Akebia aims to capture a significant portion of this market with vadadustat, pending regulatory approvals.
Upturn SWOT Analysis
Strengths
- Oral HIF-PH inhibitor platform
- Experienced management team
- Potential for improved patient convenience
- Partnerships for commercialization
Weaknesses
- Regulatory uncertainty surrounding vadadustat
- Competition from established injectable therapies
- Reliance on partnerships for commercial success
- Financial status
Opportunities
- Expanding indications for vadadustat
- Partnerships for commercialization in new territories
- Acquisition by larger pharmaceutical company
- Positive clinical trial results
Threats
- Regulatory setbacks
- Competition from other HIF-PH inhibitors
- Pricing pressures from payers
- Clinical trial failures
Competitors and Market Share
Key Competitors
- AMGN
- FGEN
- XOMA
Competitive Landscape
Akebia faces competition from established injectable ESAs and other emerging oral HIF-PH inhibitors. Success hinges on demonstrating superior efficacy and safety, as well as securing favorable reimbursement.
Growth Trajectory and Initiatives
Historical Growth: Akebia's historical growth is tied to clinical development milestones and partnership agreements.
Future Projections: Future growth is heavily dependent on regulatory approval of vadadustat and commercialization efforts. Analyst estimates vary based on these factors.
Recent Initiatives: Recent initiatives include seeking regulatory approval for vadadustat and establishing commercial partnerships.
Summary
Akebia is a biopharmaceutical company focused on developing vadadustat, an oral HIF-PH inhibitor for anemia due to CKD. Its future success hinges on regulatory approval, market adoption, and successful commercial partnerships. The company faces competition from established injectable therapies and other emerging oral treatments. Akebia needs to secure partnerships to help in the market and it needs to look out for clinical setbacks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is approximate and based on available estimates. Forward-looking statements are subject to change without notice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Akebia Ther
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2014-03-20 | CEO, President & Director Mr. John P. Butler MBA | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 181 | Website https://www.akebia.com |
Full time employees 181 | Website https://www.akebia.com | ||
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.